Orca Bio raised $250 million to support the commercial launch of its cell therapy for complications following allogeneic stem cell transplants. The financing is explicitly sized to fund launch activities rather than early R&D, signaling Orca’s expectation of near-term revenue generation and scale-up. Company statements framed the round as de-risking commercialization and expanding manufacturing and market access capacity.